Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-0072-2
Annals of Surgical Oncology 15:2804-2810 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caralt, M.
Right arrow Articles by Charco, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Caralt, M.
Right arrow Articles by Charco, R.

Original Article

Hepatic Resection for Liver Metastases as Part of the "Oncosurgical" Treatment of Metastatic Breast Cancer

Mireia Caralt, MD1, Itxarone Bilbao, PhD1, Javier Cortés, PhD2, Alfredo Escartín, PhD1, JoséLuís Lázaro, MD1, Cristina Dopazo, PhD1, Jorge Juan Olsina, PhD1, Joaquim Balsells, PhD1 and Ramon Charco, PhD1

1 Department of Hepatobiliopancreatic Surgery and Transplants, Hospital Universitari Vall d’Hebron, Paseo Vall d’Hebron119-129, Barcelona 08035, Spain
2 Department of Oncology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Correspondence: Address correspondence and reprint requests to: Mireia Caralt, MD; E-mail: mcaralt{at}vhebron.net

Background: Metastatic breast cancer is considered an incurable disease despite new therapies. Recent studies suggest that liver resection associated with systemic treatment may improve patient survival.

Patients and methods: Patient selection criteria were: good performance status, the feasibility of a complete and safe surgical procedure, and absence of uncontrolled extrahepatic metastases. The information was collected prospectively and analyzed retrospectively from our database.

Results: Between 1988 and 2006, 13 liver resections were performed in 12 patients owing to metastatic breast cancer. Two patients had synchronous metastases and ten metachronous metastases. One patient had extrahepatic bone metastases at the time of liver resection. Median follow-up was 35.9 months (range 12–113.4 months). Median age at liver resection was 58.4 years (range 36–76 years). Median hospital stay was 8 days (range 6–24 days); two patients had biliary leak but none died during the postoperative course. Seven patients (58.3%) developed hepatic recurrence. One-, 3-, and 5-year actuarial patient survival was 100%, 79%, and 33%, respectively. Patients who developed liver metastases within the first 24 months and after the first 24 months post-breast surgery had 1-, 3-, and 5-year actuarial patient survival of 100%, 0%, and 0% and 100%, 83%, and 60%, respectively (P < 0.025).

Conclusion: Liver resection for breast cancer liver metastases has an important role in the oncosurgical treatment of metastatic breast cancer with excellent 3-year survival.

Key Words: Liver metastases • Breast cancer • Surgical treatment






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.